Login to Your Account

Eylea strong playa; results with combo phase II study low hurdle for Regeneron?

By Randy Osborne
Staff Writer

Thursday, August 4, 2016

With Eylea for wet AMD ringing up global sales of $1.32 billion in the second quarter, handily above the $1.26 billion consensus estimate, Regeneron Pharmaceuticals Inc. fielded questions from analysts.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription